{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:02:57Z","timestamp":1791327777208,"version":"4.3.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T00:00:00Z","timestamp":1348185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Describe the setting in which the use of peginterferon-alfa-2b is appropriate for melanoma patients.Define the expectations with regard to survival and side effect profile in patients with melanoma receiving peginterferon-alfa-2b.<\/jats:p>\n                  <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>On March 29, 2011, the U.S. Food and Drug Administration approved peginterferon alfa-2b (PEG-IFN) (Sylatron\u2122; Schering Corporation, Kenilworth, NJ) for the adjuvant treatment of melanoma patients with microscopic or gross nodal involvement following definitive surgical resection including complete lymphadenectomy.<\/jats:p>\n                  <jats:p>The approval was based on a single, open-label, multicenter trial enrolling 1,256 patients. After surgical resection, patients were randomized (1:1) to either PEG-IFN or observation for 5 years. PEG-IFN, 6 \u03bcg\/kg per week, was administered s.c. for eight doses, followed by 3 \u03bcg\/kg per week for up to 252 weeks.<\/jats:p>\n                  <jats:p>Stratification factors included microscopic or gross nodal involvement, number of positive nodes, Breslow thickness, ulceration, sex, and study center. Patients were assessed for recurrence by the investigators based on physical examination every 3 months for 2 years and every 6 months thereafter.<\/jats:p>\n                  <jats:p>The relapse-free survival (RFS) interval, the primary efficacy endpoint, was significantly longer in PEG-IFN\u2013treated patients. The median RFS times were 34.8 months and 25.5 months, respectively. There was no statistically significant difference in the overall survival time.<\/jats:p>\n                  <jats:p>The most common (&amp;gt;60%) grade 1\u20134 adverse reactions were fatigue, increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST), pyrexia, headache, anorexia, myalgia, nausea, chills, and injection site reactions. The most common serious adverse reactions were fatigue, increased ALT and AST, and pyrexia. Thirty-three percent of patients receiving PEG-IFN discontinued treatment as a result of adverse reactions. Five deaths were reported within 30 days of the last treatment dose, two resulting from cardiovascular disease considered as possibly related to treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0123","type":"journal-article","created":{"date-parts":[[2012,9,22]],"date-time":"2012-09-22T03:37:42Z","timestamp":1348285062000},"page":"1323-1328","source":"Crossref","is-referenced-by-count":85,"title":["U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma"],"prefix":"10.1093","volume":"17","author":[{"given":"Thomas M.","family":"Herndon","sequence":"first","affiliation":[{"name":"a Office of Oncology Drug Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne G.","family":"Demko","sequence":"additional","affiliation":[{"name":"a Office of Oncology Drug Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Jiang","sequence":"additional","affiliation":[{"name":"b Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[{"name":"b Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Gootenberg","sequence":"additional","affiliation":[{"name":"a Office of Oncology Drug Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Cohen","sequence":"additional","affiliation":[{"name":"a Office of Oncology Drug Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Keegan","sequence":"additional","affiliation":[{"name":"a Office of Oncology Drug Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"a Office of Oncology Drug Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,21]]},"reference":[{"key":"2021122308124220700_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122308124220700_B2","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122308124220700_B3","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1200\/JCO.2009.24.9326","article-title":"Adjuvant interferon in high-risk melanoma: End of the era?","volume":"28","author":"Janku","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308124220700_B4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.5732\/cjc.010.10169","article-title":"Adjuvant interferon therapy for malignant melanoma: The debate","volume":"29","author":"Zhou","year":"2010","journal-title":"Chin J Cancer"},{"key":"2021122308124220700_B5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"2021122308124220700_B6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2021122308124220700_B7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.10663","article-title":"Treating cancer with PEG Intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation","volume":"95","author":"Bukowski","year":"2002","journal-title":"Cancer"},{"key":"2021122308124220700_B8","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1200\/JCO.2002.07.070","article-title":"Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials","volume":"20","author":"Lens","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122308124220700_B9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2009.10.004","article-title":"Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma","volume":"46","author":"Kaehler","year":"2010","journal-title":"Eur J Cancer"},{"key":"2021122308124220700_B10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"2021122308124220700_B11","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group","volume":"27","author":"Bottomley","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308124220700_B12","volume-title":"Ovarian Cancer Endpoints Workshop April 26, 2006 Meeting Summary"},{"key":"2021122308124220700_B13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1634\/theoncologist.2009-0120","article-title":"Approval summary: Imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors","volume":"15","author":"Cohen","year":"2010","journal-title":"The Oncologist"},{"key":"2021122308124220700_B14","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308124220700_B15","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0123","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/10\/1323\/41858318\/oncolo_17_10_1323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/10\/1323\/41858318\/oncolo_17_10_1323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T20:04:51Z","timestamp":1640289891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/10\/1323\/6400884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,21]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2012,9,21]]},"published-print":{"date-parts":[[2012,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0123","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,10,1]]},"published":{"date-parts":[[2012,9,21]]}}}